Laxxon Medical is a pharma-technology company pioneering cutting-edge 3D screen printing development and manufacturing solutions for the pharmaceutical industry. Laxxon was founded in 2017 by a team of medical and business professionals, all of whom have 20+ years experience in the pharmaceutical industry. Our highly skilled team provides comprehensive pharmaceutical services to pharmaceutical partners including R&D, IP, and regulatory services. Laxxon is headquartered in New York City with research and development facilities in Jena, Germany. We are in the process of establishing a state-of-the-art GMP lab and production facilities in the US with our partner, Evonik Industries.
Laxxon’s SPID®-Technology (Screen Printing Innovational Drug Technology) is a cutting-edge patented 3D screen printing technology which facilitates different pharmaceutical forms of application such as oral, transdermal, and implantable dosage forms through geometric shaping and heterogeneous distribution of active ingredients. SPID®-Technology is capable of printing small batches for R&D, up to commercial-scale production (up to 1.5MM units per day) without the need to change the manufacturing process.
Laxxon is dedicated to revolutionizing the pharmaceutical industry through better, faster and cost-effective solutions which mutually benefit the patient and the industry.
Laxxon’s business model is based upon a three-solution framework:
Laxxon owns the exclusive worldwide rights for the development, production and commercialization of innovative drug delivery systems on the basis of a worldwide patented large-scale 3D screen printing technology (SPID®-Technology).